<DOC>
	<DOCNO>NCT02584842</DOCNO>
	<brief_summary>The purpose study determine retrospectively application rivaroxaban endovenous laser ablation without miniphlebectomy safe lower risk venous thrombosis .</brief_summary>
	<brief_title>Rivaroxaban Endovenous Laser Ablation With Without Miniphlebectomy</brief_title>
	<detailed_description>Rivaroxaban orally active direct factor Xa inhibitor , use thrombosis prophylaxis example set orthopaedic surgery . In observed situation Rivaroxaban apply dosage 10mg daily 5 day endovenous laser ablation .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Varicose Veins</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Patients age great 18 year , inform consent give . Endovenous Laser Ablation ( EVLA ) great saphenous vein ( GSV ) , autologous saphenous vein ( ASV ) and/or small saphenous vein ( SSV ) use 1470 nm wavelength radial laser ( ELVeS , Biolitec , Austria ) postinterventional Endothermal Heat Induced Thrombosis ( EHIT ) prophylaxis rivaroxaban . Patients ineligible : endovenous ablation technique EVLA , vein GSV , ASV SSV treat EVLA ( i.e . perforators ) , postinterventional EHIT prophylaxis prophylactic dose rivaroxaban informed consent give .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>